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Abstract
Anthrax toxin receptors act as molecular clamps or switches that control anthrax toxin
entry, pH-dependent pore formation, and translocation of enzymatic moieties across the
endosomal membranes.

The ectodomain of anthrax toxin receptor 2 (ANTXR2) is

composed of a von Willebrand factor A (VWA) domain that binds to anthrax toxin
protective antigen (PA) and a newly defined immunoglobulin-like (Ig) domain, in which
the disulfide bonds are required for PA pore formation and for the folding of ANTXR2.
While the VWA domain has been well characterized, the structure and function of the
whole ectodomain (VWA-Ig) are poorly defined, this is mainly due to the limited
production of the soluble recombinant protein of the ectodomain.

In order to overcome

this, the ANTXR2 ectodomain was fused to the C-terminus of bacterial Trigger Factor
(TF), a chaperone that mediates the ribosome-associated, co-translational folding of
newly synthesized polypeptides in E. coli.

Under the control of a cold shock promoter,

the fusion protein was overly expressed as a dominant soluble protein at a low
temperature in the oxidative cytoplasm of Origami B cells, where formation of the
disulfide bonds is favored. Through a series of chromatography, the ANTXR2
ectodomain was purified into homogeneity.

The purified ectodomain is functional in

binding to PA and mediating PA pore formation on the liposomal membranes, and the
yield is applicable for future biochemical and structural characterization. We have also
previously reported that reduction of the disulfide bonds in the immunoglobulin-like (Ig)
domain of the anthrax toxin receptor 2 (ANTXR2) inhibited function of the protective
antigen (PA) pore, as measured by release of K+ ions from liposomes and from Chinese
hamster ovary (CHO) cells, or by the pore-mediated translocation of a model substrate
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across the plasma membranes. Therefore, the disulfide linkage in the Ig domain was
identified as Cys255-Cys279 and Cys230-Cys315.

Deletion of C255-C279, but not

C230-C315, inhibited the PA pore-induced release of the fluorescence dyes from the
liposomes, suggesting that C255-C279 is essential for PA pore function.

Further, we

found that deletion of C255-C279 did not affect PA prepore-to-pore conversion, but
inhibited PA pore membrane insertion by trapping the PA membrane-inserting loops in
proteinaceous hydrophobic pockets.

Fluorescence spectra of Try59, a residue

adjacent to the PA-binding motif in von Willebrand factor A (VWA) domain of ANTXR2
showed that deletion of C255-C279 resulted in a significant conformational change on
the receptor ectodomain.

The disulfide deletion-induced conformational change on the

VWA domain was further confirmed by single-particle 3D reconstruction of the
negatively stained PA-receptor heptameric complexes. This study elucidates a novel
mechanism for anthrax inhibition through modulating receptor disulfide bonds.
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Chapter 1: Introduction
1.1 Bacillus anthracis
Anthrax, a lethal disease of humans and animals, is caused by the gram-positive
spore-forming eubacterium, Bacillus anthracis (1).

It is the only obligate pathogen from

the genus Bacillus that can grow in both aerobic and anaerobic conditions. The
bacterial cell morphology includes a poly-D-gamma-glutamic acid protein capsule,
which is unique in only a few bacterial species that has a width of 1–1.2 µm and a
length of 3–5 µm (2, 3).

B. anthracis forms endospores that begin to develop and

mature inside the rod shape form and are known to be highly resilient, able to survive at
extreme temperatures, low-nutrient environments, and harsh chemical treatment over
decades or centuries. In addition, endospores are able to resist heat, drying, and
many disinfectants, such as ethanol. Anthrax is a biological threat since it has been
used as a biological weapon in both powdered and aerosol forms (4, 5).
Cellular division or endospore formation begins when either environmental
conditions are favorable or the bacteria are exposed to radicals in the environment
including oxygen.
begin to germinate.

Once this occurs the bacteria will come out of a dormant state and
At this point the cells grow and divide, and produce anthrax

protein toxins, which will be later discussed in details.
There are three types of anthrax infection, which are cutaneous, pulmonary, and
gastrointestinal (6).

The first is the most common form of the disease and is

represented by localized, inflammatory, black, necrotic lesion. Pulmonary is the most
severe form and can be described as sudden, massive chest edema followed by
1

cardiovascular shock (7).

Finally, gastrointestinal anthrax, which is very rare in

humans but very common in livestock, is still fatal when spores are ingested. The
infection process begins when spores go through phagocytosis by macrophages where
they germinate. Then bacteria escape from macrophages and multiply in tissues.
Treatment at this point can be done with antibiotics, such as penicillin or others effective
against Gram-positive bacteria (8).

If infection is not treated, both bacteremia and

toxin accumulation cause death approximately one week after infection.

Currently, an

effective anti-toxin is yet to be developed.

Illustration 1.

Forms of anthrax disease and progression. As stated above there are three ways in which anthrax can cause

disease, cutaneous, gastrointestinal and pulmonary. The diagram shows each important step in the course of the disease all the
way to the “point of no return” and death.

1.2 Anthrax Toxin

2

B. anthracis genome consists of a single circular chromosome and two large
plasmids, pXO1 and pXO2, which are required for full virulence (9, 10, 11).

Both are

part of two distinct plasmid families, in which pXO1 contains the genes coding for the
anthrax toxin components, pag (protective antigen, PA), lef (lethal factor, LF), and cya
(edema factor, EF), located within a pathogenicity island (PAI) (12). In addition, the
PAI also encodes for both a transcriptional activator AtxA and a repressor PagR, which
regulate the expression of the toxin (13, 14, 15, 16, and 17).

On the other hand, pXO2

contains a five-gene operon (capBCADE) for the biosynthesis of the poly-γ-d-glutamic
acid (polyglutamate) capsule as previously mentioned (18). This structure is very
important since it aids the ability to evade the host immune system and also protects the
vegetative cells from phagocytic killing by macrophages (19).

pXO2 also has a PAI, in

which the capsule operon and the transcriptional regulators AcpA and AcpB reside for
the capsule expression, and the last two are also activated by the previously mentioned
AtxA in pXO1 (14, 20, 21, 22).
Anthrax toxin is a tripartite A-B toxin, composed of two catalytic moieties, edema
factor (EF) and lethal factor (LF), and a receptor binding/pore-forming moiety, protective
antigen (PA) (23).

LF is a zinc-dependent metalloprotease that cleaves members of

the mitogen-activated protein kinase kinase family (all MKKs except MEK5) which
inhibits the activation of this cellular pathway as well as other cellular metabolic
processes. Once this occurs, LF is responsible of causing necrosis to the cell and
therefore causing cell death. On the other hand, EF is a calmodulin and calcium–
dependent adenylate cyclase that raises cyclic adenosine monophosphate levels within

3

the cell and causing loss of extracellular communication.

Subsequently, the cell

retains water which causes swelling and edema (25, 26).
1.3 Anthrax Toxicity
The first step of intoxication involves binding of the 83-kD PA (PA83) to a cellsurface receptor, where it subsequently undergoes cleavage by furin or a furin-like
protease to generate a 63-kD PA subunit (PA63) that spontaneously assembles into a
ring-like heptameric or octomeric structure, termed PA(63)7 prepore (26). Then, both
LF and EF bind to the PA heptamer. The entire toxin-receptor complex is internalized
by receptor-mediated endocytosis (27, 28).

The toxin complex is trafficked to the

acidic endosomal compartment where low pH induces a conformational change in the
PA(63)7 prepore. This leads to the insertion of a 14 strand beta-barrel pore into the
endosomal membrane that resembles a mushroom-shape form.

Finally, both EF and

LF are translocated into the cytoplasm where their catalytic activity takes place (29–31).

4

Leppla, 2000
Illustration 2. Anthrax toxin action once bound to a cell surface receptor.

1.4 Significance and Anthrax Vaccine
According to the Centers for Disease Control and Prevention (CDC), B. anthracis
is classified as one of seven category A agents that are considered major threats as
bioweapons (32). In 2001, the organism was used as a biological weapon targeting
the Postal Service System in the United States of America, with 22 reported cases
including the death of five people.

Therefore, it is necessary to understand this

bacterial agent and its pathogenic pathways in order to discover a readily available
5

therapeutic agent in case of a massive attack.
Administration licensed an anthrax vaccine.

So far, the U.S. Food and Drug

This anthrax vaccine adsorbed (AVA;

BioThrax) is composed of filtrate culture supernatant from B. anthracis and mostly
contains PA as well as EF and LF, but in small detectable amounts (33, 34). The AVA
vaccine is extremely reactogenic, and adverse reactions to the anthrax vaccine have
been reported in both male and female receivers over long periods of time (35, 36, 37,
38, 39, 40, and 41). With this in mind, it is well understood that AVA is not an efficient
preventive vaccine to the disease.

In addition, other groups have reported library

screening compounds, which inhibit anthrax toxin action, but not in a significant way
(42, 43).
1.5 Anthrax Toxin Receptors
Anthrax toxicity and disease progression is highly mediated by two cellular
receptors for PA interaction that have been identified: anthrax toxin receptor 1
(ANTXR1) and anthrax toxin receptor 2 (ANTXR2) (44, 45).

ANTXR1 is also termed

tumor endothelial marker 8 gene (TEM8), and ANTXR2 is termed as capillary
morphogenesis protein two (CMG2).

The two human receptors are 40% identical

overall, but share 60% identity in the von Willebrand factor A (VWA)-like region where
PA binding occurs (44, 45).

Both ANTXR1 and ANTXR2 contain a domain that is

homologous to the I domain of integrin receptors, which comprises a Rossmann-like
α/β-fold with a metal-ion-dependent adhesion site (MIDAS) motif on the upper surface
(46).

Both receptors are type-I transmembrane proteins, comprising an extracellular

domain (ectodomain), a single-pass transmembrane domain, and a cytoplasmic domain
(23).

Most human cells appear to express ANTXR2 (45) and ANTXR1 has been
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reported to be expressed in human epithelial cells of the lungs, skin, intestines (47) and
in endothelial cells (48).
In spite of the overall identity, ANTXR2 has a much higher affinity for PA (Kd = 0.170
nM compared to Kd = 130 nM for ANTXR1) (49).

Crystal structures of the VWA

domain of ANTXR2, and the PA-VWA complex have been determined (50, 51).
Recently, it has been shown that the lethality of anthrax toxin for mice is primarily
mediated by ANTXR2 and that ANTXR1 plays only a minor role (52).
1.6 Hypothesis
The goal of the project is to characterize the disulfide bonds within the
ectodomain (extracellular domain) of ANTXR2. The ANTXR2 ectodomain is composed
of two domains, an N-terminal VWA domain (termed R218 from now on) and an
immunoglobulin-like factor domain (Ig). There are total seven cysteine residues in the
ectodomain (termed R318 from now on), with three in the VWA domain and four in the
Ig domain.

7

Illustration 3.

Schematic of anthrax toxin receptor 2 (ANTXR2).

A. ANTXR2 is composed of a PA-binding VWA domain

(residues 38-218), an Ig domain (residues 219-318), a single-pass transmembrane domain (TM, 319-343) and a cytoplasmic
domain (Cyto, 344-489).
R318.

For simplicity, here VWA domain is termed as R218, and the whole ectodomain, VWA-Ig, is termed as

B. The amino acid sequence of ANTXR2 ectodomain, R318. The residues in the Ig domain are bolded and the Cys

residues are highlighted.

Previous work has identified that there is a disulfide bond in the VWA domain, however,
very little is known about the formation of disulfide bond(s) in the Ig domain (23).
Furthermore, there has not been any type of structural characterization for R318. It is
also not clear which disulfide bond(s) in R318 is required for toxin pathogenesis.
Current work from Sun et. al (23) has suggested that the disulfide bonds in the
ectodomain of R318 are required for the anthrax toxin action.

Therefore, the

objective of this study is to determine the linkage pattern of the disulfide bonds,
and identify the disulfide bond(s) that is/are required for anthrax toxin action.
These findings can give us insights into understanding the overall structure of R318 and
the role of disulfide bonds in toxin action.
1.7 Specific Aims
-Specific Aim 1: Express and purify R318
-Specific Aim 2: Characterize and map the disulfide bonds of R318
-Specific aim 3: Investigate the role of the disulfide bonds of R318 in anthrax toxin
action.
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Chapter 2: Cloning, Expression and Purification of R318
2.1 Challenges of R318 expression and purification
Previous study has shown that although the VWA domain is highly soluble, R318
is expressed in Escherichia coli as an insoluble protein with only a minimal amount of
soluble product. We believe this is due to mis-folding of the protein, probably caused
by incorrect disulfide bond formation.

Sun et. al., have previously expressed and

purified the wild type (WT) soluble R318 protein using a maltose binding protein (MBP)
as a fusion tag, but the yield is low (23).
Both immobilized metal affinity chromatography and size exclusion chromatography
have been used in purifying R318, but the purification protocol has not yet been
optimized.

It is of great interest to produce a properly folded protein, which will be

used in studies of the roles of the receptor disulfide bonds in anthrax toxin action.
2.2 Materials and Methods
2.2.1 R318 Cloning
R318 cDNA encoding residues 38-318 was amplified by PCR and inserted into a
pMALc2x vector (NEB), at EcoRI and Hind III restriction sites (Illustration 4). What is
special about this vector is that R318 was expressed as a fusion with a N-terminal MBP
(42kD) and a C-terminal 6 Histidine-tag.
R318-His6 (~72kD).

Therefore, the construct is termed, MBP-

This construct is expressed in the cytoplasm of E. coli strain.

9

Illustration 4. pMALc2x expression vector.

R318 was cloned into EcoRI and Hind III restriction sites. The vector expresses

an MBP-fusion protein along with a strong “tac” promoter and the malE translation initiation signals, to give high levels of soluble
proteins.

In addition, we have acquired E. coli Origami B (DE3) cells (Novagen) that are a specific
strain carrying mutations in the genes of thioredoxin reductase (trxB) and glutathione
reductase (gor), giving the cytoplasm an oxidized environment therefore favoring
disulfide bond formation.
Alternatively, R318 was cloned into pCOLD-TF vector (Illustration 5) (Takara),
using NdeI and XhoI restriction enzymes.

This specific vector expresses Trigger

Factor, which is a 48kD prokaryotic ribosome-associated chaperone protein, as a
soluble fusion tag, and facilitates co-translational folding of newly expressed
polypeptides.

In addition, the vector has a cspA (cold shock protein A) promoter,

which allows for up-regulation of target proteins at low temperatures.

In addition,

Trigger Factor carries a N-terminal 6-histidine tag for affinity purification. There are
three protease cleavage sites (Factor Xα, Thrombin and HRV 3C) between Trigger
Factor and the multiple cloning sites, so Trigger Factor can be cleaved off the target
protein after purification.
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Based on the characteristics of this vector we expressed the TF-R318 fusion protein at
a low temperature (16˚C).

Illustration 5. pCOLD TF expression vector. R318 was cloned into NdeI and XhoI restriction sites.

pCOLD expresses the

chaperone Trigger Factor as a fusion tag and has a cspA (cold shock protein A) promoter which allows for up-regulation of target
proteins at low temperatures.

Aside from these two R318 constructs, we also generated a number of different
constructs to express R318 in Origami B (DE3) (Table 1).
Table 1.

List of the primers used to clone R318 into its respective expression vectors with given sequences and restriction

enzymes.

2.2.2 R318 cell transformation
Next we performed a transformation of all of the R318 plasmid constructs in
Origami B (DE3) by placing 2 μL of DNA into 30 μL of cells into a 1.5 mL
microcentrifuge tube and incubated on ice for 20 min. Then we heat shocked the
sample at 42°C in an analog heatblock (VWR) for 45 seconds and then incubated on ice
11

for an additional 5 minutes. Then we added 970 μL of Luria-Bertani (LB) media and
incubated at 37°C at 220 rpm for one hour in a 1585 Shaker Incubator (VWR).

After

one hour, we centrifuged the tube at 14,800rpm in Microfuge 16 centrifuge (Belkman
Coultier) for 2 minutes and removed the media.

Then we resuspended the cell pellet

with 50 μL of ddH2O and plated the cells in a LB agar plate with 100 μg/ml carbenicillin
(Goldbio). The agar plate will be incubated overnight (<16 hours) at 37°C in a general
purpose incubator (VWR).
2.2.3 R318 small- and large-scale cell growth, and induction
The following day we selected a colony and inoculated 10 mL of LB media with
100 μg/mL of carbenicillin and incubated at 37°C at 220 rpm overnight (<16hours).
We did a small scale expression of the protein in 50mL of LB media in order to check for
expression.

On the following day we inoculated 49 mL of LB media with 1 mL of the

overnight bacterial culture (1/50) and added 100 μg/mL of carbenicillin into a glass flask.
Then, we placed the flask culture into a shaker incubator at its respective temperature
at 220 rpm until the OD600 reaches 0.6-0.8. We then induced protein expression by
adding Isopropyl β-D-1-thiogalactopyranoside (IPTG) at various concentrations and
continue shaking for various length of time at indicated temperatures.
We first did titrations on induction temperature, IPTG concentrations, and time.
Our temperature titrations included 37, 30, 25, 20, and 16°C.
included 1mM, 0.1mM, and 0.01mM.

Our IPTG titrations

Finally, our time titrations ranged from 3, 6

hours, and overnight (<18hours) depending on the induction temperature. The titrated
parameters for R318 expression were listed in Table 2:
Table 2. R318 different expression variables. First row represents temperature, first columns represent IPTG final
concentrations and columns subsequent columns represent induction time course. o/n= overnight
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R318

37°C

30°C

25°C

20°C

16°C

0.01mM IPTG

3 hours

6hours

o/n

o/n

o/n

0.1mM IPTG

3hours

6hours

o/n

o/n

o/n

1mM IPTG

3hours

6hours

o/n

o/n

o/n

For pCOLD TF-R318, we followed the same transformation, starter culture and
small scale procedures as previously stated, but induced at 15°C for 18 hours with 1mM
IPTG.
Large scale expression for purification purposes was done with 4-liters of LB media, and
the cultures were induced at 15°C for 18 hours with 1mM IPTG once the OD600 reached
0.8.

Cells were harvested and stored at -80°C.
2.2.4 R318 purification
For the purification process we resuspended the cell pellet in 3-5mL/g of cell

pellet in Buffer A (20mM Tris HCl pH 7.3, 300mM NaCl, 10mM Imidazole) (Sigma
Aldrich), 1mg/mL of lysozyme (Sigma Aldrich) and a pinch of
phenylmethanesulfonylfluoride (Sigma Aldrich), and sonicated with a Vibracell VCX 750
sonicator (Sonics) using a 1/4inch sonicator tip at 40% amplitude for 30 minutes. Then
we separated the total cell lysis into soluble and insoluble fractionations by centrifuging
the cell extract in a Sorvall RC 6+ (Thermo Scientific) centrifuge in a SS34 rotor at
19,000rpms for one hour at 4°C. We collected the supernatant and discarded the
insoluble pellet. We then prepared a General Electric 16XK (GE Healthcare) 75mL
IMAC sepharose (GE Healthcare) 250mM Nickel Sulfate (Sigma Aldrich) charged
column and equilibrated with 5 column volumes of Buffer A using a minipulse 3
peristaltic pump (Gilson) at 5ml/min.

Once completed, we loaded our soluble fraction
13

into the column.

In addition, the flow through fraction was also collected to test if our

protein was being bound to the column.

Once the entire soluble fraction sample was

loaded into the column, we used a General Electric AKTA Fast Polypeptide Liquid
Chromatography (GE Healthcare) to continue with the purification process.
The FPLC machine will be set to function at 5mL/min with a pressure no more than
0.3mPa.

First the column was washed with 5 column volumes (375mL) of Buffer A,

and then we set an elution gradient of 10% to 60% Buffer B (20mM Tris HCl pH 7.3,
300mM NaCl, 500mM Imidazole) (Sigma Aldrich) to elute our protein of interest. The
AKTA FPLC device aliquots the elutions automatically and we checked for purification
of our protein of interest on 12% SDS-PAGE gels.
In order to further purify our protein of interest, we continued with Size Exclusion
Chromatography by using a General Electric XK 26/60 column (GE Healthcare) packed
with 330mL bed size of Superdex 200 media (GE Healthcare).

This type of media has

excellent gel filtration properties and is a combination of cross-linked dextran with the
physical and chemical stabilities of highly cross-linked agarose.

In addition, purification

of globular proteins range is from 10,000 to 600,000 Da.

Therefore, since our

recombinant protein has an estimated molecular weight of 72kD, this form of gel
filtration was expected to be ideal for us. We used the previously described AKTA
apparatus with the standard gel filtration manufacturers protocol using Gel Filtration
Buffer (20mM Tris HCl pH 7.3, 150mM NaCl) (Sigma Aldrich) at a flow rate of
0.5mL/min, a pressure no more than 0.3mPa, and an elution gradient of 1.5 column
volumes (495mL).
2.3 Results
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2.3.1 Small scale expression of R318 in different protein expression
vectors in Origami B cells.
R318 was essentially insoluble when it was expressed alone in pET22b, or as a
GST-fusion protein in the cytoplasm of E. coli, even at the temperature as low as 15°C.
We hypothesize that the disulfide bonds in the Ig domain of R318 play an important role
in protein folding and solubility, while the reducing environment of the cytoplasm
disfavors formation of the disulfide bonds. The low yield of R318 protein could be
attributed to one or more of the factors, such as low efficiency of protein transport from
the cytosol to the periplasm, the small space of the periplasm relative to the cytoplasm,
and the low efficient disulfide bond formation, etc. To increase the yield of R318, we
tested the expression of R318 in the Origami B strain of E. coli (Figure 1).

Origami B

strain carries the trxB/gor mutations that delete the activities of glutathione reductase
and thioredoxin reductase, which greatly enhances disulfide bond formation in the
cytoplasm.

Moreover, Origami B strain contains characteristics of lacZY deletion

mutants of E. coli BL21 that enable adjustable levels of protein expression by titrating
IPTG concentrations. Surprisingly, when induced with 0.1 mM IPTG at 15°C, R318
with either a His-tag (R318-His6) or a GST-tag (GST-R318) was still insoluble (Figure 1
A and B).

MBP-R318 was expressed in a low level, and the western blot showed that

only 10% of MBP-R318 was in soluble faction (Figure 1C).

After all of the

unsuccessful attempts, we cloned the gene encoding R318 into the pCOLD-TF (trigger
factor) vector to express a TF-R318 fusion protein under the control of the cspA cold
promoter.

After induction with 1 mM IPTG at 15°C, the fusion protein was
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overexpressed in Origami B cells and the majority of TF-R318 was in soluble fraction
(Figure 1D).

Figure 1.

TF-R318 under the control of a cold promoter is expressed as the most soluble protein.

fusion tags were expressed in Origami B cells as indicated.
were harvested, lysed and fractionated by centrifugation.

R318 with different

A. R318-His6; B. GST-R318; C. MBP-R318; D. TF-R318. The cells

The whole cell lysates (W), soluble fraction (S) and insoluble pellet (P)

were subjected to SDS-PAGE, followed by Coomassie blue staining.

The fusion proteins were marked with arrows.

Expression

of MBP-R318 was further confirmed by western blot using an HRP-conjugated anti-MBP antibody (C).

2.3.2 R318 was purified into homogeneity through a series of
chromatography.
The large-scale expression of TF-318 was performed in 4-liters of LB medium,
where TF-R318 in Origami B cells was induced at OD600 0.6-1.0 with 1 mM IPTG at 15
°C for 16-24 hours.

At such a low temperature, expression of most endogenous

proteins was inhibited, but expression of TF-R318 under the control of the cspA cold
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promoter was highly activated.

At the time of harvest, TF-R318 was account for about

¼ of the total soluble proteins (Table III and Figure 2B). The soluble lysate was first
applied to a nickel column, and the His-tagged TF-R318 was purified by immobilizedmetal affinity chromatography (IMAC) (Figure 2A).

The eluted TF-R318 appeared to

be a mixture of soluble oligomeric TF-R318, termed (TF-R318)n, and monomeric TFR318, which were further separated by a sizing exclusion chromatography using a
Superdex 200 column (Figure 2C).

In SDS-PAGE without the reducing agent, the

oligomeric (TF-R318)n was run as a smear with various oligomeric forms, while in the
presence of the reducing agent, the majority of the oligomeric (TF-R318)n was reduced
and run as a single monomeric band, suggesting that majority of the oligomeric (TFR318)n was formed by cross-linking of the inter-molecular disulfide bonds (Inserted
figures in Figure 2C). The monomeric TF-R318 was cleaved by Factor Xα and
passed through a nickel column, in which the His-tagged uncut TF-R318 and the free
TF were retained in the column and the free R318 was collected in flow through.
Finally, the free R318 was purified into homogeneity by a sizing exclusion
chromatography using a Superdex 75 column (Figure 2D).
Table 3.

Summary of Purification of TF R318/R318.
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Figure 2.

R318 was purified into homogeneity through a series of chromatography.

A. The N-terminally His-tagged TF-

R318 was purified by an immobilized-metal affinity chromatography (IMAC) using a Ni-sepharose column.

The soluble fraction of

cell lysate containing TF-R318 was applied to a Ni sepharose column, followed by wash and elution with an imidazole gradient in an
AKTA FPLC unit. The majority of TF-R318 was eluted at 30-60% of Buffer B containing 500 mM imidazole.

B. After purification

by IMAC, the samples of whole cell lysate (W), supernatant (S), flow through (FT), wash and elute, were collected and applied to
SDS-PAGE to analyze the purification efficiency.

As a control, the cell lysates (W and S) before IPTG induction were also

analyzed to show the IPTG-inducible expression of TF-R318.

C. The TF-R318 eluted from the Ni-column was concentrated and

applied to a Superdex 200 column for sizing exclusion chromatography, in which the soluble oligomeric (TF-R318)n and the
monomeric TF-R318 were separated.

Insert Figures: the oligomeric (TF-R318)n and monomeric TF-R318 were analyzed by

SDS-PAGE with or without DTT, followed by Coomarssie blue staining.
and then passed through a Ni-column to remove the His-tagged TF.

D. The monomeric TF-R318 was incubated with Factor Xα,

The free R318 was collected in flow through.

further purified by a sizing exclusion chromatography using a Superdex 75 column.
protein and was purified to nearly homogeneity as shown in SDS-PAGE.
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R318 was

R318 was eluted as a ~ 30 kDal monomeric

2.4 Discussion
The structural and functional analysis of the Ig domain of ANTXR2 is significantly
hindered due to the limited production of the recombinant ectodomain, R318.

R318

was fused to the bacterial chaperone Trigger Factor, and over-expressed the TF-R318
fusion protein at a low temperature under the control of a cold-shock promoter in the
cytoplasm of Origami B cells, where formation of disulfide bonds is favored.

This

newly developed protocol has significantly increased the solubility of R318 and allowed
us purify the functional R318 into homogeneity, which will facilitate biochemical and
structural characterization of R318 in future.
When expressed as a GST-tagged protein in E. coli, R218 is soluble, but R318 is
not soluble, suggesting that the Ig domain play a major role in the folding of the whole
ectodomain.

The insolubility of R318 in E. coli was apparently attributed to the

reducing cytoplasm of E. coli, where disulfide bond formation is not favored. While the
periplasm is regarded as an oxidative environment favoring disulfide bond formation,
protein production in the periplasm is usually lower than that in the cytoplasm due to a
number of reasons, especially when target protein has a poor solubility and requires
expression at a low temperature with a low concentration of IPTG. Thus, Origami B
strain that contains a modified oxidative cytoplasm becomes an attractive host for
expressing target proteins that contain disulfide bonds.

It was surprising that R318-

His6, GST-R318 and MBP-R318 were still not soluble when expressed in Origami B
cells, even with low IPTG induction and at a low temperature. This strongly suggests
that in addition to the disulfide bonds, other factors also play an important role in the
folding of R318 in E. coli. We have tried co-expression of R318 with the plasmid pG-
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KJE8 (Takara) that encodes a set of chaperones (dnaK-dnaJ-grpE-groES-groEL) in
Origami B cells, but the solubility of R318 was not improved (data not shown).

The

observation that fusing R318 to the Trigger Factor significantly increased the solubility
of R318 indicates that the TF-mediated co-translational folding of the newly synthesized
polypeptide of R318 is the rate-limiting step for producing correctly folded R318 in E.
coli.

It is worthy of mentioning that expression of a His-tagged R318 in the pCOLD

vector (with the cspA cold shock promoter, but without TF fusion) did not produce
soluble R318 (data not shown).

This again strongly suggests that TF is the unique

chaperone that is required for correct folding of R318 at the translational step. One
can image that in the process of translation, TF mediates the folding of the backbone of
the R318 polypeptide and brings the pairs of the Cys residues for disulfide bond
formation in the Ig domain to close proximity, allowing formation of the disulfide bonds.
And the formation of the disulfide bonds in turn stabilizes the folding of the protein
backbones.
Expression of target protein at low temperature is a common approach to
increase solubility of target protein in E. coli.

However, there is a trade-off between

solubility and productivity, which has to be carefully balanced.

In this study, the trade-

off was resolved by application of the cspA cold shock promoter that overly expressed
TF-R318 at 16°C, a temperature where expression of the most endogenous proteins
was repressed.

Thus, TF-R318 was expressed as a dominant soluble protein in the

cells, which greatly increased the productivity and facilitated purification.
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Chapter 3: Structural Characterization of R318
3.1 Identifying the disulfide bond linkage of R318.
As previously stated, R318 has seven cysteine residues that form three disulfide
bonds (23). The specific residues are C39, 175, 218, which are in the VWA-R218
region, and it is well established that C39 and C218 form a disulfide bond meanwhile
175 remains as a free thiol (51). Furthermore, C230, C255, C279, C315, are residues in
the Ig-like domain, in which Sun et. al. (23) have reinforced that C175 remains as a free
thiol by using Ellman’s reagent, and that the six other cysteine residues form three
disulfide bonds.

In addition, they also concluded that these two disulfide bonds might

be important for toxin pore formation once inside the acidic cellular compartment (23).
The exact pairing of the four disulfide bonds in the Ig-like domain of R318 remains
elusive.

In addition, there is no known structural data of R318, which makes it difficult

to develop a mechanism to understand toxin action. With that in mind, it is important to
map out the disulfide bond linkage in R318, in order to further investigate the role of the
disulfide bonds in anthrax toxin action.
3.2 Materials and Methods
3.2.1 R318 Cysteine to Alanine mutants
Cysteines in the Ig-like domain of R318wt were mutated to Alanine residues in
pCOLD TF by using Quickchange mutagenesis kit (Agilent Technologies) following
manufacturer’s protocol.

Mutations were confirmed by sequencing. Expression and

purification of R318 mutants were done as previously mentioned in R318wt.
3.2.2 Tryptophan fluorescence
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5 µM of R218, R318, the C/A mutants of R318 were treated with/without 10 mM
TCEP in 20 mM Tris-HCl, 100 mM NaCl, pH 7.3. Emission spectra of Trp59
fluorescence were recorded in an ISS-K2 multiphase frequency and modulation
fluorometer from 300-370 nm with excitation at 290 nm. The spectra were calibrated
using the same buffers with/without TCEP.
3.3 Results
3.3.1 The residues C255/C279 and C230/C315 form two disulfide bonds in
the Ig domain of ANTXR2
To determine the exact disulfide pairing in the Ig domain, we generated a series
of mutations by replacing Cys with Ala two at a time in all possible combinations:
C230A/C255A, C230A/C279A, C230A/C315A, C255A/C279A, C255A/C315A,
C279A/C315A.

As a control, we also replaced all of the Cys residues with Ala, which

generated the 4C/A mutant.

Following the previously described procedures, we

expressed and purified the recombinant receptor ectodomains with respective C/A
mutations in E. coli. While all of the proteins were expressed at a similar level in E.
coli, only the proteins with mutations C230A/C315A, C255A/C279A and 4C/A were
purified as soluble monomeric proteins (Figure 3B, 3C).

And the rest of the mutants

failed to be purified, because they formed aggregations in the cells, which was primarily
due to mis-folding and/or disulfide crosslinking.

Moreover, a mass spectrometry

analysis of the purified R318 recovered 55% of the sequence, in which two trypsindigested polypeptides were linked by the disulfide bond formed by C255 and C279.
Together, this result suggests that C230/C315 and C255/C279 form two stable disulfide
bonds in the Ig domain (Figure 3A).

The disulfide linkage is consistent with the results
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in a recent report (53), in which C230/C315 and C255/C279 were predicted to form two
disulfide bonds by homologous modeling and by expression of the receptor genes
containing C/A mutations in mammalian cells.

Figure 3.

The residues C255/C279 and C230/C315 form two disulfide bonds in the Ig domain of ANTXR2.

A. Sequence of

ANTXR2 showing that C255/C279 and C230/C315 form two disulfide bonds in the Ig domain. B. Coomassie blue stained SDSPAGE of purified TF-R318 and the (C/A) mutants of TF-R318 as indicated. C. Coomassie blue stained SDS-PAGE of R318 and
the (C/A) mutants, further purified through removal of TF tag.

3.3.2 Reduction or deletion of C255-C279 resulted in a significant
conformational change on the receptor ectodomain.
Trp59 is located at the top of VWA domain that is close to the PA binding
interface, and it is the only Trp residue in the whole ectodomain.

Here, we tested the

intrinsic fluorescence of Trp59 to monitor the conformational changes induced by
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disulfide disruption. The spectra of Trp59 fluorescence on R218, R318,
R318(C230/315A), R318(C255/279A), and R318(4C/A) were measured in the presence
or absence of TCEP (Figure 4).

R218 is not responsive to TCEP treatment, which is

consistent with the previous finding that C39-C218 is dispensable for maintaining the
VWA structure (49, 51).

R318 underwent a significant conformational change upon

TCEP treatment, evidenced by a shift of the spectrum peak from 320 nm to 330 nm.
R318(C230/315A) displayed spectra that were similar to R318, suggesting that deletion
of C230-C315 did not affect the receptor conformation.

However, R318(C255/279A)

without TCEP treatment has a spectrum peak at 330 nm, and it made no additional
conformational change upon TCEP treatment, indicating that deletion or reduction of
C255-C279 was responsible for the receptor conformational change.

As predicted,

R318(4C/A) had a spectrum peak at 330 nm in the presence or absence of TCEP.
The result clearly demonstrated that the disulfide bond C255-C279, in either forming or
breaking, is responsible for two distinct conformations of the receptor ectodomain,
Conformation 1 (C1) with the spectrum peak of Trp59 at 320 nm or Conformation 2 (C2)
at 330 nm.
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Figure 4.

Deletion of C255-C279, but not C230-C315, resulted in a significant conformational change on the receptor

ectodomain.

5 µM of the purified receptor domains were incubated in the 20 mM TrisHCl (pH 7.3), 100 mM NaCl, in the presence

or absence of 5 µM TCEP. The intrinsic Trp59 fluorescence spectrum was measured with excitation at 290 nm and emission at
300-370 nm.

Note: two distinct spectrum peaks (320 nm and 330 nm) were detected and represented as two distinct

conformations, denoted as C1 and C2.

3.5 Discussion
In this chapter, we have determined the disulfide bond linkage in R318wt using
different R318 cysteine mutants that were created and purified as previously described.
We believe that mutation in C230/315A of R318 did not cause a change in conformation
in the receptor structure, but mutation in C255/279A of R318 did. This is evidenced by
the tryptophan fluorescence study (Figure 4), in which native R318wt and
R318(C230/315A) follow the same red shift spectra as both native or disulfide bond
reduced VWA.

But, R318(C255/279A) and 4C/A could not fulfil this red shift neither in

their native nor reduced state.

This justifies that the tryptophan in these last two

mutants must be more solvent exposed whether the mutants are reduced or not, and
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therefore having a similar structure. This also indicates that these reduced forms of
R318wt and mutants cause an effect on the VWA structure. We would also like to
mention that in addition to this structural data, we collaborated with Dr. Chuan Xiao from
the Chemistry Department at the University of Texas at El Paso, in which in silico
analysis has indicated that the residues 219-318 form an Ig fold (23, 53), its structure
and position in the PA-receptor heptameric complex are still unknown.

Using single-

particle 3D reconstruction, we determined a low-resolution map (~14Å) of PA-R318
heptameric complex, using negatively stained samples (Figure 5C, E, G).

Figure 5. Homology modeling of the Ig domain and docking of the atomic structure into the reconstructed EM maps. A. The
structure of the Ig domain is generated by homologous modeling and grafted to the crystal structure of the VWA domain through
energy minimization. The secondary structure is colored as α-helices in orange, β-sheets in purple and loops in grey.

The disulfide

bonds C39-C218, C255-C279 and C230-C315 are shown as stick models, colored in yellow. Note: Trp59 is shown in a sphere
model and labeled. B, D, and F are ribbon diagrams of PA-R318 heptameric complex viewed from top, bottom and side,
respectively. C, E, and G are surface rendered density maps from reconstruction of negatively stained PA-R318 heptameric
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complex, docked with the modeled structure and viewed from top, bottom and side, respectively. Segmented map density of one
subunit of the receptor ectodomain is shown on up-right in E or lower-left in G, respectively. The map was rendered at the level of
one standard deviation above the average density value of the map. Within the PA heptamer, each of the seven monomers are
colored in red, orange, yellow, green, cyan, magenta, and purple, respectively. The VWA domains and the Ig domains are colored in
blue and green, respectively.

The reconstructed EM maps are rendered in magenta.

In parallel, we generated a structural model of ANTXR2 ectodomain by homology
modeling (Figure 5A).

The modeled Ig domain in combination with the crystal

structure of PA-VWA heptameric complex was docked in the reconstructed EM map
(Figure 5 B-G).

Apparently, the modeled Ig domain fit into the additional density

underneath the complex.

We also noticed that the density of the Ig domain was

significantly weaker than that expected by molecular weight and only appeared when
the contour level of the map drop to one standard deviation above the average density
level, while the other part of the complex can be rendered at three and half standard
deviation above the average density level and still fit the atomic model very well.

This

suggests that the Ig domain is flexible in solution compared to PA and the VWA domain.
This is consistent with the structural model, in which the hinge region between VWA and
Ig allows certain flexibility between the two domains. We hope to further obtain highresolution structural data by crystallography or other methods. This would also help us
better understand what other residues in the R318 structure might be affected upon
mutation or reduction of the disulfide bonds. Most importantly, it can help us develop a
structural mechanism in which reduction of the disulfide bonds in R318 might have upon
anthrax toxin action.
Chapter 4: Investigating the role of the disulfide bonds in R318 in anthrax toxicity
4.1 Understanding the influence of the disulfide
anthrax toxin action.
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bonds in R318 towards

Sun et. al have previously described that upon reduction of the disulfide bonds in
R318, there is inhibition of pore formation in the toxin/receptor complex in both
synthesized lipids and CHO-ANTXR2 cells (23).

Yet, it is unknown if the reduction of

R318 inhibits the conformational change of the toxin/receptor complex, or if the
conformational change occurs as well as the pore formation, but the pore is blocked and
there is no toxin translocation.

It is not known which of the two processes happen due

to the reduction of the receptor.

In addition, we also do not know which of the two

disulfide bonds in the receptor are crucial for pore formation, or if both are required in
order for this step to occur. Preliminary data shows that there might be a correlation
between the disulfide bonds in the receptor and the mechanism in toxin translocation in
a cellular acidic compartment.
4.2 Materials and Methods
4.2.1 Protective antigen purification and preparation
PA was cloned into pET22b, and then transformed into BL21 (DE3) (NEB) E. coli
cells using the previously mentioned transformation protocol. They were plated and
later grown in a 115 Fermentor/Bioreactor 2.5 liter fermentor (BioFlo/CelliGen).

Then

the cells were grown at 37°C and when OD600 reaches 1, the temperature was lowered
to 30°C and induced with 1mM IPTG. The induction time was 4 hours and cells were
harvested and lysed by Osmotic Shock (30). Furthermore, PA was then purified by
Anion Exchange Chromatography using Buffer A (20mM Tris HCl, pH 8.5) and eluting
with Buffer B (20mM Tris HCl, pH 8.5, 1M NaCl) (49).
Next, in order to form PA prepore heptamer (PA63) from wild type (PA83), we
digested PA using the protease trypsin at 1:1000 v/v, and incubated the digested
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reaction at room temperature for 30 minutes. Finally, for the purification of (PA63)7, we
purified the digested sample by Anion Exchange Chromatography following the same
purification protocol as previously stated (54).
4.2.2 Pyrene fluorescence
PA83 carrying the mutation N306C was labeled with pyrene as previously
described with labeling efficiency 80–90% (55). The pyrene-labeled PA83 protein was
treated with trypsin and then purified as (PA63)7 heptamer with ion exchange
chromatography.

The pyrene-labeled (PA63)7 was incubated with R218, R318, and the

C/A mutants of R318 at pH 8.5 for 30 mins. Conversion of prepore to pore in solution
was triggered by addition of 1/10 volume of 1 M sodium acetate (pH 5.0). Pyrene
fluorescence emission was recorded at 540 nm with excitation at 342 nm.
4.2.3 Liposome preparation
Liposomes were prepared as previously described (23, 56, 57).

Briefly, DOPC

2+

was mixed with Ni -chelating lipids, DOGs-NTA-Ni (1,2-dioleoyl-sn-glycero-3-{[N(5amino-1-carboxypentyl) iminodiacetic acid-]succinyl nickel salt})

with a molar ratio

100:8 in chloroform (Avanti Polar Lipids). The lipid was dried under N2 gas to form a
lipid film, followed by vacuum for 3 h to remove residual solvent. The dried lipid film
was rehydrated with the buffer containing 50 mM of ANTS and DPX to form
multilamellar vesicles and subjected to three freeze-thaw cycles and extrusion through a
200-nm pore size polycarbonate filter (Nucleopore) in a mini extruder (Avanti Polar
Lipids). The protocol yielded large unilamellar vesicles with an average diameter of
150–200 nm.
4.2.4 Time-lapse intensity measurement of NBD emission
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PA83 proteins carrying the mutation G305C or N306C were labeled with IANBD
as previously described with labeling efficiency 80–90% (60, 61).

Then the NBD-

labeled PA83 proteins were treated with trypsin and then purified as (PA63)7 heptamers.
NBD emission of PA pores in the liposomal membranes was measured as previously
described (60, 61). Briefly, 0.2 µM of (PA63)7 was pre-incubated with 1.4 µM of R218His6, R318-His6, or the C/A mutants at pH 8.5 for 30 mins, and then incubated with the
Ni2+-liposomes for another 30 mins. The protein-liposome mixtures were transferred to
a cuvette with a stirring bar in the ISS K2 fluorometer.

NBD was excited at 488 nm,

and emission was recorded at 544 nm. Crossed polarizers on excitation, emission
beams, and a 520-nm filter were used to reduce the background scatter.

After addition

of 1/10 volume of 1 M sodium acetate (pH 5.0) to the cuvette, the shift of NBD label
from a polar (solution) to a nonpolar environment (liposomal membrane) was monitored.
Rates of NBD emission were calculated in SigmaPlot by fitting the curves to the single
exponential equation f=y0+a*[1-exp(-b*x)], in which b is the rate of NBD emission at 544
nm.
4.2.5 ANTS/DPX fluorescence dequenching
The ANTS fluorescence dequenching assay for PA pore formation was
developed as previously described (56, 57). Briefly, (PA63)7 was pre-incubated with
R218-His6, R318-His6, and the indicated C/A mutants with a molar ratio of receptor/PA
at 3:1 in 20 mM Tris-HCl (pH 8.5), 150 mM NaCl, 1mM MgCl2, at room temperature for
30 mins. Then 100 μl of the liposomes doped with ANTS/DPX were incubated with the
protein mixture for an additional 30 mins. The protein/liposome mixture was diluted
into 1.3 ml of 20 mM TrisHCl (pH 8.5), 150 mM NaCl, 1 mM MgCl2 with continuous
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stirring in the ISS-K2 fluorometer with excitation at 380 nm and emission at 520 nm.
After the base line was stabilized, 200 μl of 1M NaAc (pH 5.0) was injected into the
cuvette, and the fluorescence signal was monitored in real-time. Crossed polarizers on
excitation and emission beams, and a 435-nm long path filter were used to reduce the
background scatter.
4.3 Results
4.3.1 Deletion of C255-C279, but not C230-C315, inhibited the PA poreinduced dequenching of ANTS fluorescence.
To measure PA pore function, we recently adopted a sensitive, convenient
ANTS/DPX fluorescence dequenching assay as a replacement of the K+ release assay
that was previously established in the laboratory (56, 57).

ANTS/DPX, the anion/cation

fluorophore/quencher pair, is widely used for membrane leakage. ANTS fluorescence
is quenched by DPX inside the liposomes, and it is dequenched upon release into the
medium. We have shown that ANTS/DPX fluorescence-dequenching assay faithfully
replicated the results obtained from the K+ release assay (56, 57). Here we used this
assay to determine effects of disulfide deletion on functioning of PA pore (Figure 6).
As expected, PA alone caused a low level of ANTS fluorescence dequenching, which
was due to pore formation on the liposomal membranes by a portion of the acidificationconverted PA pores through random encounters with the membranes.

Compared to

PA alone, the PA complexed with either R218 or R318 induced significantly higher
fluorescence. The result was consistent with the previous findings that reconstitution
of PA to the liposomal membranes through interaction of the His-tags on the receptor
domains with the Ni2+-chelating lipids on the liposomal membranes greatly enhanced
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PA pore formation (23).

However, when PA was bound to disulfide deletion mutants

either R318(C255/C279) or R318(4C/A), the dequenching of ANTS fluorescence was
drastically inhibited, to a level that is even lower than that of PA alone. Again, this result
is consistent with our previous findings, where reduction of R318 by TCEP or DTT
inhibited the PA-induced K+ release (23).

Interestingly, deletion of C230/C315 only has

a partial effect on dequenching of ANTS fluorescence. Together, this data suggests
that the disulfide bond C255/C279 is required for functioning of PA pore.

Figure 6.

Deletion of C255-C279, but not C230-C315, inhibited the PA pore-induced fluorescence dequenching in the

liposomes.

The heptameric prepore (PA63)7 was bound to the purified receptor domains as indicated, and then incubated with the

liposomes doped with ANTS/DPX.
nm with excitation at 380 nm.

Pore formation was triggered by acidification, and ANTS dequenching was measured at 435

The representative curves of ANTS fluorescence were displayed in A; ANTS fluorescence at 60

seconds of post-acidification from three repeats were quantified and shown in B.

4.3.2 Disulfide deletion did not affect PA prepore-to-pore conversion.
Next, we sought to test effects of the disulfide deletion on PA prepore-to-pore
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conversion.

Formation of SDS-resistant oligomers in SDS-PAGE is a well-documented

marker for PA prepore-to-pore conversion (55, 62, 63).

Previously, we have found that

reduction of the receptor by TCEP did not affect PA prepore-to-pore conversion either in
solution or on the cell surface membranes (23).

Consistent with this result, here we

found that deletion of either C255-C279 or C230-C315, or both, did not affect formation
of the SDS-resistant oligomer at low pH (Figure 7A).

To further confirm effects of the

disulfide deletion on PA prepore-to-pore conversion, we used pyrene fluorescence to
monitor the kinetics of the PA conformational transition in real time.

Pyrene is a

spatially sensitive extrinsic fluorescent probe, which forms excited-state complexes
(excimers) upon close encounter with other pyrene molecules. In a previous study,
pyrene maleimide was attached to the residue N306C located on the PA 2β2-2β3 loop.
The pyrene labels are too far apart in the prepore structure to interact, but their
proximity within the β-barrel of the pore leads to excimer formation and fluorescence
(55, 64).

Here, we monitored the prepore-to-pore conversion using the pyrene-labeled

PA(N306C) that was bound to the receptor domains as indicated (Figure 7B, C).
Compared to R218 and R318, deletion of either or both of the disulfide bonds in the Ig
domain did not exert a significant effect on pyrene fluorescence upon acidification.
The result of pyrene fluorescence is consistent with that of the above mentioned SDSresistant form.

In summary, disulfide deletion did not affect PA prepore-to-pore

conversion.

33

Figure 7.

Disulfide deletion did not affect PA prepore-to-pore conversion.

A. (PA63)7 was incubated with the purified

receptor domains as indicated in pH 8.5 buffer for 30 minutes in the presence of 1 mM MgCl2. The pH of the buffers either
remained constant or dropped to pH 5.0.
followed by Coomassie blue stain.

Subsequently, the formation of SDS-resistant oligomers was examined in SDS-PAGE,

B. The pyrene labeled PA(N306C) heptamer was bound to R218, R318 and the R318 C/A

mutants as indicated in pH 8.5 buffer.

Conversion of prepore to pore was triggered by acidification (pH 5.0) and measured by

pyrene fluorescence at 470 nm with excitation at 342 nm.

The representative curves of pyrene fluorescence were shown in B.

The pyrene fluorescence intensity at 15 seconds of post-acidification was quantified and shown in C.

4.3.3 Disulfide deletion did affect insertion of PA pore into the membranes.
Since disulfide deletion did not affect PA prepore-to-pore conversion, we tested if
it affects PA pore membrane insertion.

NBD is an environment-sensitive dye, with
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excitation at 488 nm, the emission intensity of NBD fluorescence at 544 nm increases
substantially upon a shift from a polar (aqueous) to a non-polar (lipid) environment.
Here we used NBD fluorescence to test the effects of disulfide deletion on PA pore
insertion on the liposomal membranes. As previously described (60, 61), NBD was
attached to the lipid-facing position of PA pore, G305C.

As expected, PA alone

showed little NBD fluorescence, while the R318-bound PA showed a significantly higher
NBD fluorescence.

Compared to R318, however, the mutants with deletion of either

C255-C279 or C230-C315, or both, produced comparable levels of NBD fluorescence
(Figure 8).

At this point we believed that the disulfide bonds did not have an effect on

membrane insertion by PA, until we repeated the assay without liposomes.
Unexpectedly, it showed that mutants C255-C279 and 4C/A gave NBD fluorescence
even when the liposomes were not present. This proves to us that the NBD molecule
inserts into a hydrophobic pocket within the toxin/receptor complex and therefore acting
as if it were inserted in the membrane. With this in mind, it justifies that pore insertion
is inhibited and that the disulfide bonds impact the membrane pore insertion by PA. As
a negative control, we also tested the PA with NBD labeled on N306C, a residue facing
the aqueous lumen of the pore.

As expected, the NBD-labeled PA(N306C), when

bound to R318 or the C/A mutants, did not exhibit any NBD fluorescence (data not
shown), indicating that the pattern of PA pore membrane insertion is not affected.
Together, the data suggest that disulfide deletion did affect PA pore insertion to the
membranes.
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Figure 8.

Disulfide deletion did affect membrane insertion of PA pore.

The NBD-labeled PA(G305C) heptamer was

complexed with the receptor domains as indicated in pH 8.5 buffer. The PA-receptor complexes were pre-bound to the liposomes
through binding of the His-tags on the receptor domains to the Ni-chelating lipids on the membranes.

Membrane insertion was

triggered by acidification (pH 5.0). The NDB fluorescence was measured at 544 nm with excitation at 488 nm. The representative
curves of NDB fluorescence were shown in A.

The curves were fit to the single exponential equation f =ya*[1exp(b*x)], and the

rates of NBD.

4.4 Discussion
In summary, we have found that mutant R318C255/279A has an effect on the PA
pore forming complex.

Initially we believed that this disulfide bonds played a role in

blocking the PA pore, based on the ANTS/DPX and potassium release assay, but to our
surprise it was not until the NBD assay which helped us understand that this specific
bond inhibited the insertion of the PA pore. Therefore, we believe that the disulfide
bond mutation does not affect the pore formation and conformational change of PA, but
might have an effect on the 14-strand beta barrel inserting into the membrane.

More

on the collaboration with Dr. Xiao, we observed the conformational changes induced by
disulfide disruption, we first reconstructed the EM maps for the heptameric complexes
of PA-TF-R318 and PA-TF-R318(4C/A) (Figure 9A-F).
36
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Figure 9. 3D reconstruction of negatively stained PA-TF-R318 and PA-TF-R318(4C/A) detected the disulfide deletion-induced
conformational changes on the VWA domain. A, C, and E are surface rendered density maps of PA-TF-R318 heptameric complex viewed
from top, bottom and side. B, D, and F are surface rendered density maps of PA-TF-R318(4C/A) viewed from top, bottom and side.
structure of the PA-VWA heptameric complex was docked in the reconstructed maps.

The crystal

G is the side view of the superposed density maps from

PA-TF-R318 (transparent grey) and PA-TF-R318(4C/A) (solid green). H is the side view of the superposed density map from PA-TF-R318
(transparent grey) and PA-R318 (solid magenta) showing no significant difference. I and K are the zoom-in monomeric view for the area at the
lower part of the complexes as show in G and H respectively. J is the ribbon diagram of the fitted PA and VWA structure at the same orientation
and magnification as in I and K. All of the maps were rendered at the level of three and half times standard deviation above the average density
value of the maps. The PA is colored in red and the VWA is colored in blue. Trp59 of VWA is rendered as spherical model and labeled.

We have described how Trigger factor has improved the solubility and stability of R318
proteins, especially for the R318 Cys/Ala mutants (57).

Moreover, TF tag at the N-

terminus of R318 did not affect the function of the receptor in mediating PA pore
formation (data not shown).

More importantly, TF tags appeared to increase the

visibility and orientations of the protein particles on the EM grids after negative staining.
Surprisingly, however, in the reconstructed EM map of PA-TF-R318 we could not locate
the density of Ig domains and TF tags (Figure 9A, C, E). We noticed that in the
pCOLD-TF vector there is an extended polypeptide linker (26 residues in total) between
TF and the inserted gene. This long linker may cause significant flexibility between TF
and receptor, which made density mapping of the structures beneath the VWA domains
difficult, especially when the maps were rendered at a low contour level.

Nevertheless,

we rendered the map of PA-TF-R318 at a density level of three and half standard
deviation above the average value to remove the disordered density beneath the VWA
domains. The resultant map of PA-TF-R318 fits the crystal structure of the PA-VWA
heptamer very well (Figure 9A, C, E).

Using the same parameters, we reconstructed

the EM map of PA-TF-R318(4C/A) (Figure 9B, D, E).
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Compared to the map of PA-TF-

R318, PA-TF-R318(4C/A) apparently has less density in the VWA domain (Figure 9G, I
and J), suggesting that the VWA domain on the 4C/A mutant was either partially
unfolded and/or became more flexible.
from Trp59 fluorescence experiment.

This observation is consistent with the data
To rule out the possibility that TF tags may

interfere with the density mapping, we compared the reconstructed maps of PA-R318
and PA-TF-R318 by superimposing the two maps rendered at a three and half standard
deviation above average density level (Figure 9H and K).

The superimposed map

shows that there is no significant difference between two maps, suggesting that the
presence of the flexible TF tags did not affect the density mapping of PA and VWA.
Chapter 5: The importance of the disulfide bonds in both R318 folding and
anthrax toxicity.
Our study began by taking into consideration the importance of redox reactions in
cell surface receptors and their ability to internalize extracellular content into the cell.
These redox reactions serve as on and off switches within cell surface receptors in
either inhibiting or activating this cellular process.

Disulfide bonds serve as a form of

these specific switches. With this in mind, we believed that the disulfide bonds in R318
might play a role in the cellular mechanism of internalizing the anthrax toxins into the
cell.

Before this study, it was believed that R318 formed three disulfide bonds out of

seven cysteine residues Figure 3A (23).
disulfide bonds were unknown.

The exact mapping or orientations of these

More importantly though was the fact that upon

reduction of these disulfide bonds, anthrax toxin pore was blocked in lipid membranes,
toxin translocation was inhibited across mammalian cells (23).

At this point we

believed that in fact R318 was one of these cell surface receptors that have a role in

39

these redox reactions, and that the disulfide bonds in R318 might be important for
anthrax toxicity.

But before we continued into further characterizing the disulfide bonds

in this receptor and understanding their role with anthrax toxicity, we encountered the
challenge of producing fully soluble and functional R318 protein.

Expressing and

purifying R318 in a bacterial host has become one of the most difficult tasks in this
study.

This is due to the fact that R318 forms disulfide bond cross-linking between

different R318 monomers which leads to oligomerization of the product Figure 2C.
Furthermore, it is important to address that not only is this the reason why R318
becomes insoluble, but also because the protein does not become properly folded
inside the host cell.

That is, that even upon treating the oligomers with reducing agent

the oligomers a fraction of the oligomers still remains (data not shown).

This

phenomenon was not further investigated but we believe that it might have to do with
some type of hydrophobic interaction between oligomers. We also learned that the
receptor is very dynamic and that it can go into redox reactions if its environment is
neglected which makes it very unstable. Although it was difficult in overcoming the
challenges brought to us in isolating this receptor, both the Origami B strain and the
pCOLD vector worked for us successfully.

We believe that the Trigger Factor aided as

a chaperon in the proper folding and also disulfide bond linkage, and that the Origami
strain provided the exact redox environment inside the cell in favor of the receptor.
addition, these two variables also produce fully functional soluble receptor.

In

At this

point, we were ready to continue with our structural and biochemical receptor studies.
Our next interest in this study was to map out and characterize the disulfide bonds in
R318.

As previously mentioned, we only had to determine the formation of the
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disulfide bonds in the Ig-domain of R318, since one disulfide bond (C39/218) is formed
in the VWA domain of the receptor and residue C175 remains as a free thiol (23).
Therefore we wanted to create these different cysteine mutants in order to not only
identify the proper formation of these disulfide bonds, but also to test their functionality
in regards to anthrax toxicity.

Although we were able to create the different mutant

DNA constructs, only three receptor mutants were purified including the 4C/A mutant
Figure 3B and C.

Because of the nature of the receptor in proper folding and

solubility, we began to believe that these two mutants followed the proper disulfide bond
linkage in R318.

One reason was the fact that we could not purify the others since

they all became misfolded proteins inside the host cell (data not shown).

So in order to

confirm this hypothesis we decided to do Homolog Remodeling on R318 Figure 5A.
As predicted, the VWA follows the known homologous I domain of integrin receptors
composed of a Rossmann-like α/β-fold in which beta-sheets are surrounded by alpha
helices, and a metal-ion-dependent adhesion site (MIDAS) motif on the upper surface.
Furthermore, the Ig-like domain is composed of antiparallel beta-sheets and is much
smaller than the VWA domain.

In addition, this structure also gave the predicted

disulfide bond pattern between residues C39/218, C230/315 and C255/279.

Further

structural characterization lead to the EM reconstruction of the PA heptamer and R318
in both ribbon and density maps Figure 5B-G.

This specific structure was overlaid

with the known PA-VWA complex and proved that the Ig domain is weaker and more
solvent exposed in this complex Figure 5E and G.

Nonetheless, this structure helps

us understand where in the complex does the Ig domain rest and how it is incorporated
as well.

Once we had discovered the disulfide bond mapping and structural
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characterization of the PA heptamer and R318 complex, we decide to further study the
role of the disulfide bonds in the Ig domain. Before we began our biochemical studies,
we decided to test if there are any changes in conformation in the receptor if any of the
disulfide bonds were missing, or both.

We have described earlier that there is a

Tryptophan residues at position 59 in the VWA, and is can be used to measure
conformational changes in proteins based in its exposure to the environment. We saw
that R318 had two distinct conformations based on its absorption spectra. Both R318
wild type and mutant C230/315 had the same absorption spectra in their native form,
but changed similarly when they became reduced.

On the other hand, R318 mutants

C255/279 and 4C/A had the same absorption spectra in both native and reduced forms.
This means that W59 will become more solvent exposed upon reduction of R318 wild
type and the C230/315 mutant but is more embedded in their native state. Whereas it
is always more solvent exposed in the other two mutants in both native and reduced
forms, suggesting that there is a change in receptor conformation upon deletion of
residues C255/279 in R318. This type of structural data has not been investigated in
depth before and has brought us great insights into the structure and orientation of the
Ig domain in R318 which is an important aspect of this study.

More importantly though

is the fact of the role of the disulfide bonds in anthrax toxin action.
As previously mentioned, if the disulfide bonds in R318 are reduced chemically, anthrax
toxin action is inhibited (23).

Therefore a very important goal of this project was to

identify not only which disulfide bond is responsible, but also at which step is the toxin
action inhibited.

Ultimately, we hoped to build a possible inhibition mechanism by

answering these two questions.

So our initial study began by identifying which
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disulfide bond in R318 was responsible in blocking the anthrax toxin pore Figure 6.
Here we saw that mutant C255/279 had a severe reduction in fluorescence signal than
the C230/315 and even more surprisingly the C4/A mutant.

At this point we realized

that not only does the C255/279 mutant cause a noticeable conformational change in
the receptor structure, but also that it has the ability to block the anthrax toxin pore in
some way.

At this point we believed that this mutant actually simply blocked the

anthrax toxin pore and could serve as a possible pore inhibitor of the toxin.

In order to

fully elucidate other possibilities of this mutant in anthrax toxin action, we decided to
break down the important step in anthrax toxin action.

At this point we knew that both

the wild type and mutant receptors binded to PAwt and the PA heptamer. And that
they had an effect on the PA heptamer pore action in the leakage assay Figure 6.

So

continuing on, we wondered if it had an effect on the conformational change of the PA
heptamer in the pre-pore to pore conversion.

To investigate this in a sensitive and

efficient manner, we decided to use a fluorescent probe that can measure
conformational changes in proteins as well as distances or proximities from one
another; this probe is Pyrene (65).

Pyrene has the ability to form excimers upon

coming to proximity with another molecule of its kind, so if a pyrene molecule becomes
excited, it will transmit its excitation to another pyrene molecule if it encounters it but
maintains its excited state (65).

Another important fact is that the emission spectra of

the monomer and excimer pyrenes do not overlap (65). Since it has already been
established that the PA pore is approximately 12A˚ (64), pyrene can transmit
fluorescence under this proximity. With this said, we labeled N306 with pyrene, which
is a residue facing the lumen of the pore, and tested for excimer formation upon pore
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formation. This can be achieved since the PA pore will have a total of seven pyrenes
in the complex and will give excimer emission if they come in proximity to one another.
Surprisingly, we found that all PA-receptor wild type and mutant complexes were able to
emit pyrene fluorescence including the PA complex alone. This proved to us that the
C255/279 still did not cause an effect in blocking the conformational change of the PA
pore.

At this point we analyzed the fact that this mutant blocked the PA pore and not

its conformational change, but what if it inhibited the pore to be inserted into the lipid
membrane.

For this approach we used NBD which is a fluorescent probe used as a

reported to measure hydrophobic environments (61, 65).

Here NBD will emit if it is

transitioned from a polar to a nonpolar environment (61, 65).

This is a very special

phenomenon known as red-shift excitation and is described as molecule orientation in
this case NDB.

So, in polar solution NBD will form hydrogen bonds in solution but

those bonds are broken when the molecule goes into a hydrophobic environment, but
this point the molecule becomes relaxed and is able to emit (65). So like the labeling
of N306 in the pore lumen, we decided to label a residue in the PA pore, facing the lipid
membrane.

G305 is a residue that faces the lipid membrane upon pore insertion and

can be used to measure this transition (61).

Just like the pyrene assay, we noticed

that all toxin-receptor wild type and mutant complexes gave a positive emission
suggesting that the PA pore is inserted into the membrane.

At this point we believed

that the C255/279 mutant had only an effect in blocking the PA pore.

To our surprise

we repeated the assay without lipids and saw a total different result. We saw that both
the mutants C255/279 and 4C/A still gave positive emission.

So we thought if there

aren’t any lipids in our assay, and NBD is dependent of a hydrophobic environment,
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how could we still obtain a positive signal?

For this explanation we had to develop a

hypothesis based on our structural data. We believe that if the disulfide bond formed
between residues C255/279 is deleted, this causes an effect on the VWA domain of
R318 by making it loose density and becoming more solvent exposed Figure 10.

Figure 10: Compared to PA-R318, PA-R318(C255/279A) exhibited a significant conformational change on the VWA domain.
A, B, and C are surface rendered density maps of PA-R318 heptameric complex viewed from top, bottom and side in magenta. E,
F, and G are surface rendered density maps of PA-R318(C255/279A) viewed from top, bottom and side in cyan. The crystal
structure of the PA-VWA heptameric complex was docked in the reconstructed maps.

D is the side view of the superposed density

maps from PA-R318 (transparent magenta) and PA-R318(C255/279A) (solid cyan). H is the side view of the superposed density
map from PA-R318 (transparent magenta) and PA-R318(C255/279A) (solid cyan) that shows the missing densities in the VWA
domain. I is the ribbon diagram of crystal structure of PA-VWA heptamer at the same orientation and magnification as in H. All of the
maps were rendered at the level of three and half times standard deviation above the average density value of the maps. The PA is
colored in red and the VWA is colored in blue. Trp59 of VWA is rendered as spherical model and labeled.

Figures 9 and 10 are EM reconstruction maps of PA heptamer and R318 4C/A and
R318 (C255/279A) respectively, have helped us understand the importance of the
C255/279 disulfide bond in the structure of R318. Taking into consideration that both
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of these mutants have this specific disulfide bond mutated you can see how part of the
VWA domain R318 becomes more solvent exposed in the PA-receptor complex Figure
9C-F and Figure 10B-G.

This specific conformational change in the receptor structure

has given us reason to believe that it might not allow the PA pore to fully assemble
properly and become stable, and therefore not insert into the membrane. The 2β-3β
sheets in domain 2 of each of the PA monomers that form the pre-pore complex, move
towards the bottom of the PA-receptor complex and form the known 14-beta barrel
pore. We believe that the flexibility and relaxation of the VWA domain in these mutants
cause an effect on these domain 2 beta sheets to not let it assemble or insert properly.
Furthermore, we also believe that they might embed within the R318 structure at the
base of the PA-receptor complex, which gave a hydrophobic environment to the beta
sheets therefore testing positive for NBD fluorescence. In other words, the beta sheets
are going into a hydrophobic pocket provided by the toxin-receptor complex.

Our

predicted model (Illustration 6) suggests that once the PA prepore monomer is bound
to an R318 monomer through domain 4 of PA and the VWA in R318, and the
conformational change occurs upon acidification, domain 2 moves towards the bottom
of the complex and becomes β-barrel stem which gets inserted into the lipid membrane.
At the same time domain 1 which is responsible for EF and LF binding, domain 3 in PA
oligomerization and domain 4, form a cap at the upper face of the complex (31).
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Illustration 6.

The classical anthrax toxin model for membrane insertion.

Although this is the classical way in which anthrax toxin takes action, the disruption of
the disulfide bonds in the Ig domain of R318 inhibits this transition of domain 2 in PA to
insert into the lipid membrane. The exact mechanism for this is still unknown to us but
both our structural and biochemical data presented here in this study suggests it.
In a future study we hope to obtain further structural data that can help us exactly
identify what is happening to domain 2 of PA upon reduction or deletion of the disulfide
bonds in the Ig domain of R318. We are very much interested in knowing exactly
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where the beta sheets of domain 2 are imbedded within the R318 structure that do not
allow it to fully assemble into its pore shape. In addition to this, we also would want to
identify important residues in the beta sheets of PA or R318 in proper pore formation
and insertion.

Future methods we expect to conduct are either crystallography or

electron microscopy as stated in this study. An overall future direction would be to
obtain a structure of the entire complex pore which has never been found. This would
definitely aid in understanding in depth the mechanism that is caused by the deletion of
the disulfide bonds in R318.

It would also show us exactly how the pre-mature pore is

assembled once these bonds are deleted. More important is the fact that we would
like to know how the beta sheets in domain 2 of PA are imbedded prematurely in the
proteinaceous hydrophobic pockets. This has brought great interest into our study.
This report has brought us great insights in understanding an important role of R318 in
anthrax toxicity and that it must be present in order for toxicity to take effect.

In

addition, the disulfide bonds in the Ig domain of R318 are highly important in allowing
the entire toxicity mechanism to take place. We also found important structures that
aid in the change in conformation in the receptor if these disulfide bonds are absent.
We would like to add that these specific structures have never been identified. We
also found that upon deletion of the disulfide bonds in R318 causes aberrant effects on
the anthrax toxin by not letting it get inserted into the membrane. With this we hope to
continue our research to find better ways to understand anthrax toxicity and
therapeutics to it.

48

References
1. Leppla, , K. Aktories and I. Just, eds., S.H. (2000) Anthrax Toxin in Bacterial Protein
Toxins (Berlin: Springer), pp. 445–472.
2. Spencer, RC (March 2003). "Bacillus anthracis.". Journal of clinical pathology 56 (3):
182–7. doi:10.1136/jcp.56.3.182. PMC 1769905. PMID 12610093.
3. Holt, J. G., N. R. Krieg, P. H. A. Sneath, J. T. Staley, and S. T. Williams. 1994. Group
17: gram-positive cocci, p. 527–558. In W. R. Hensyl (ed.), Bergey's manual of
determinative bacteriology, 9th ed. Williams and Wilkins, Baltimore, Md.
4. Bergey's Manual of Systematic Bacteriology, vol. 2, p. 1105, 1986, Sneath, P.H.A.;
Mair, N.S.; Sharpe, M.E.; Holt, J.G. (eds.); Williams & Wilkins, Baltimore, Maryland,
USA
5. Zilinskas, Raymond A. (1999), "Iraq's Biological Warfare Program: The Past as
Future?", Chapter 8 in: Lederberg, Joshua (editor), Biological Weapons: Limiting the
Threat (1999), The MIT Press, pp 137-158.
6. National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) 2013.
Centers for Disease Control and Prevention. Accessed October 28, 2014.

<http://

http://www.cdc.gov/anthrax/types/>
7. National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) 2013.
Centers for Disease Control and Prevention. Accessed October 28, 2014.

<http://

http://www.cdc.gov/anthrax/types/inhalation.html>
8. Barnes JM (1947). "Penicillin and B. anthracis". J Path Bacteriol 194: 113–125.
doi:10.1002/path.1700590113.

49

9. Read, TD; Peterson, SN; Tourasse, N; Baillie, LW; Paulsen, IT; Nelson, KE; Tettelin,
H; Fouts, DE; Eisen, JA; Gill, SR; Holtzapple, EK; Okstad, OA; Helgason, E; Rilstone, J;
Wu, M; Kolonay, JF; Beanan, MJ; Dodson, RJ; Brinkac, LM; Gwinn, M; DeBoy, RT;
Madpu, R; Daugherty, SC; Durkin, AS; Haft, DH; Nelson, WC; Peterson, JD; Pop, M;
Khouri, HM; Radune, D; Benton, JL; Mahamoud, Y; Jiang, L; Hance, IR; Weidman, JF;
Berry, KJ; Plaut, RD; Wolf, AM; Watkins, KL; Nierman, WC; Hazen, A; Cline, R;
Redmond, C; Thwaite, JE; White, O; Salzberg, SL; Thomason, B; Friedlander, AM;
Koehler, TM; Hanna, PC; Kolstø, AB; Fraser, CM (May 1, 2003). "The genome
sequence of Bacillus anthracis Ames and comparison to closely related bacteria.".
Nature 423 (6935): 81–6. doi:10.1038/nature01586. PMID 12721629.
10. Kolstø, Anne-Brit; Tourasse, Nicolas J.; Økstad, Ole Andreas (1 October 2009).
"What Sets Apart from Other Species?". Annual Review of Microbiology 63 (1): 451–
476. doi:10.1146/annurev.micro.091208.073255.
11. Mock M, Fouet A. 2001. Anthrax Annu. Rev. Microbiol. 55:647–71
12. Okinaka RT, Cloud K, Hampton O, Hoffmaster AR, Hill KK, et al. 1999. Sequence
and organization of pXO1, the large Bacillus anthracis plasmid harboring the anthrax
toxin genes. J. Bacteriol. 181:6509–15
13. Dai Z, Sirard JC, Mock M, Koehler TM. 1995. The atxA gene product activates
transcription of the anthrax toxin genes and is essential for virulence. Mol. Microbiol.
16:1171–81
14. Fouet A, Mock M. 2006. Regulatory networks for virulence and persistence of
Bacillus anthracis. Curr. Opin. Microbiol.9:160–66
15. Koehler TM, Dai Z, Kaufman-Yarbray M. 1994. Regulation of the Bacillus anthracis

50

protective antigen gene: CO2 and a trans-acting element activate transcription from one
of two promoters. J. Bacteriol. 176:586–95
16. Mignot T, Mock M, Fouet A. 2003. A plasmid-encoded regulator couples the
synthesis of toxins and surface structures in Bacillus anthracis. Mol. Microbiol. 47:917–
27
17. Uchida I, Hornung JM, Thorne CB, Klimpel KR, Leppla SH. 1993. Cloning and
characterization of a gene whose product is a trans-activator of anthrax toxin synthesis.
J. Bacteriol. 175:5329–38
18. Candela T, Fouet A. 2006. Poly-gamma-glutamate in bacteria. Mol. Microbiol.
60:1091–98
19. Drysdale M, Heninger S, Hutt J, Chen Y, Lyons CR, Koehler TM. 2005. Capsule
synthesis by Bacillus anthracis is required for dissemination in murine inhalation
anthrax. EMBO J. 24:221–27
20. Perego M, Hoch JA. 2008. Commingling regulatory systems following acquisition of
virulence plasmids by Bacillus anthracis. Trends Microbiol. 16:215–21
22. Pannucci J, Okinaka RT, Williams E, Sabin R, Ticknor LO, Kuske CR. 2002. DNA
sequence conservation between the Bacillus anthracis pXO2 plasmid and genomic
sequence from closely related bacteria. BMC Genomics 3:34
22. Van der Auwera GA, Andrup L, Mahillon J. 2005. Conjugative plasmid pAW63
brings new insights into the genesis of the Bacillus anthracis virulence plasmid pXO2
and of the Bacillus thuringiensis plasmid pBT9727. BMC Genomics 6:103

51

23. Sun J., Collier J.R. Disulfide Bonds in the Ectodomain of Anthrax Toxin Receptor 2
Are Required for the Receptor-Bound Protective-Antigen Pore to Function. 2010.
PLoS.
24. Drum CL, Yan SZ, Bard J, Shen YQ, Lu D, et al. (2002) Structural basis for the
activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature 415: 396–402.
25. Leppla SH (1982) Anthrax toxin edema factor: A bacterial adenylate cyclase that
increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A 79:
3162–3166.
26. Milne, J. C., D. Furlong, P. C. Hanna, J. S. Wall, and R. J. Collier. 1994. Anthrax
protective antigen forms oligomers during intoxication of mammalian-cells. J. Biol.
Chem. 269:20607–20612.
27. Abrami, L., S. H. Liu, P. Cosson, S. H. Leppla, and F. G. van der Goot. 2003.
Anthrax toxin triggers endocytosis of its receptor via a lipid raft mediated clathrindependent process. J. Cell Biol. 160:321–328.
28. Gordon, V. M., S. H. Leppla, and E. L. Hewlett. 1988. Inhibitors of receptormediated endocytosis block the entry of Bacillus-anthracis adenylate-cyclase toxin but
not that of bordetella-pertussis adenylatecyclase toxin. Infect. Immun. 56:1066–1069.
29. Benson, E. L., Huynh, P. D., Finkelstein, A.&Collier, R. J. (1998) Biochemistry 37,
3941–3948.
30. Friedlander, A. M. (1986) J. Biol. Chem. 261, 7123–7126.
31. Petosa, C., Collier, R. J., Klimpel, K. R., Leppla, S. H. & Liddington, R. C. (1997)
Crystal structure of the anthrax toxin protective antigen Nature 385, 833–838.

52

32. Darling RG, Catlett CL, Huebner KD, Jarrett DG (2002) Threats in bioterrorism. I:
CDC category A agents. Emerg Med Clin North Am 20: 273–309.
33. Puziss, M., L. C. Manning, J. W. Lynch, E. Barclay, I. Abelow, and G. G. Wright.
1963. Large-scale production of protective antigen of Bacillus anthracis in anaerobic
cultures. Appl. Microbiol. 11:330–334.
34. Taft, S. C., and A. A. Weiss. 2008. Neutralizing activity of vaccine-induced
antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
Clin. Vaccine Immunol. 15:71–75.
35. Geier, D. A., and M. R. Geier. 2002. Anthrax vaccination and joint related adverse
reactions in light of biological warfare scenarios. Clin. Exp. Rheumatol. 20:217–220.
36. Geier, M. R., and D. A. Geier. 2004. Gastrointestinal adverse reactions following
anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System
(VAERS) database. Hepatogastroenterology 51:762–767.
37. Greidanus, T. G., and B. A. Honl. 2002. Delayed-type hypersensitivity reaction to
anthrax vaccine. Mil. Med. 167:74–75.
38. Muniz, A. E. 2003. Lymphocytic vasculitis associated with the anthrax vaccine:
case report and review of anthrax vaccination. J. Emerg. Med. 25:271– 276.
39. Pittman, P. R., P. H. Gibbs, T. L. Cannon, and A. M. Friedlander. 2001.
Anthrax vaccine: short-term safety experience in humans. Vaccine 20:972– 978.
40. Swanson-Biearman, B., and E. P. Krenzelok. 2001. Delayed life-threatening
reaction to anthrax vaccine. J. Toxicol. Clin. Toxicol. 39:81–84.
41. Vasudev, M., and M. C. Zacharisen. 2006. New-onset rheumatoid arthritis after
anthrax vaccination. Ann. Allergy Asthma Immunol. 97:110–112.

53

42. Min, D.H., Tang, W.J., Mrksich, M. (2004). Chemical screening by mass
spectrometry to identify inhibitors of anthrax lethal factor. Nature Biotech 22:717-723.
43. Rogers MS, Cryan LM, Habeshian KA, Bazinet L, Caldwell TP, et al. (2012) A
FRET-Based High Throughput Screening Assay to Identify Inhibitors of Anthrax
Protective Antigen Binding to Capillary Morphogenesis Gene 2 Protein. PLoS ONE 7(6):
e39911. doi:10.1371/journal.pone.0039911.
44. Bradley, K. A., Mogridge, J., Mourez, M., Collier, R. J. & Young, J. A. (2001) Nature
414 , 225–229.
45. Scobie HM, Rainey GJ, Bradley KA, Young JA (2003) Human capillary
morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S
A 100: 5170–5174.
46. Lee, J.-O., Rieu, P., Arnaout,M. A. & Liddington, R. C. Crystal structure of the Adomain from the a subunit of integrin CR3 (CD11b/CD18). Cell 80, 631–635 (1995).
47. Bonuccelli, G., F. Sotgia, P. G. Frank, T. M. Williams, C. J. de Almeida, H. B.
Tanowitz, P. E. Scherer, K. A. Hotchkiss, B. I. Terman, B. Rollman, A. Alileche, J.
Brojatsch, and M. P. Lisanti. 2005. ATR/TEM8 is highly expressed in epithelial cells
lining Bacillus anthracis’ three sites of entry: implications for the pathogenesis of anthrax
infection. Am. J. Physiol. Cell Physiol. 288:C1402–C1410.
48. Rmali, K. A., M. A. Al-Rawi, C. Parr, M. C. Puntis, and W. G. Jiang. 2004.
Upregulation of tumour endothelial marker-8 by interleukin-1beta and its impact in IL-1β
induced angiogenesis. Int. J. Mol. Med. 14:75–80.

54

49. Wigelsworth, D. J.; Krantz, B. A.; Christensen, K. A.; Lacy, D. B.; Juris, S. J.; Collier,
R. J. Binding Stoichiometry and Kinetics of the Interaction of a Human Anthrax Toxin
Receptor, CMG2, with Protective Antigen. J. Biol. Chem. 2004. 279, 23349–23356.
50. Petosa, C., Collier, R. J., Klimpel, K. R., Leppla, S. H. & Liddington, R. C. Crystal
structure of the anthrax toxin protective antigen. Nature 385, 833–838 (1997).
51.

Lacy, D. B.,Wigelsworth, D. J., Scobie, H. M., Young, J. A. & Collier, R. J. Crystal

structure of the von Willebrand factor A domain of human capillary morphogenesis
protein 2: An anthrax toxin receptor. Proc. Natl Acad. Sci. USA 101, 6367–6372 (2004).
52. Liu, S., Crown, D., Miller-Randolph, S., Moayeri, M., Wang, H., Hu, H., Morley, T.,
and Leppla, S. H. (2009) Capillary morphogenesis protein-2 is the major receptor
mediating lethality of anthrax toxin in vivo. Proc. Natl. Acad. Sci. U.S.A. 106, 12424–
12429.
53. Deuquet, J., Lausch, E., Guex, N., Abrami, L., Salvi, S., Lakkaraju, A., Ramirez, M.
C. M., Martignetti, J. A., Rokicki, D., Bonafe, L., Superti-Furga, A., and Van Der Goot, F.
G. (2011) Hyaline fibromatosis syndrome inducing mutations in the ectodomain of
anthrax toxin receptor 2 can be rescued by proteasome inhibitors. EMBO Mol Med 3,
208–221
54. Cunningham, K., Lacy, D.B., Mogridge, J. & Collier, R.J. Mapping the lethal factor
and edema factor binding sites on oligomeric anthrax protective antigen. Proc. Natl.
Acad. Sci. USA 99, 7049–7053 (2002).
55. Miller, C. J., Elliott, J. L., and Collier, R. J. (1999) Anthrax protective antigen:
prepore-to-pore conversion. Biochemistry 38, 10432–10441
56. De Leon, J., Jiang, G., Ma, Y., Rubin, E., Fortune, S., and Sun, J. (2012)

55

Mycobacterium tuberculosis ESAT-6 Exhibits a Unique Membrane-interacting Activity
That Is Not Found in Its Ortholog from Non-pathogenic Mycobacterium smegmatis. J
Biol Chem 287, 44184–44191
57. Jacquez, P., Lei, N., Weigt, D., Xiao, C., and Sun, J. (2013) Expression and
purification of the functional ectodomain of human anthrax toxin receptor 2 in
Escherichia coli Origami B cells with assistance of bacterial Trigger Factor. Protein Expr
Purif 95C, 149–155.
60. Sun, J., Vernier, G., Wigelsworth, D. J., and Collier, R. J. (2007) Insertion of anthrax
protective antigen into liposomal membranes: effects of a receptor. J Biol Chem 282,
1059–1065.
61. Qa’dan M, Christensen KA, Zhang L, Roberts TM, Collier RJ (2005) Membrane
insertion by anthrax protective antigen in cultured cells. Mol Cell Biol. 25:5492–5498.
62. Milne, J. C., Furlong, D., Hanna, P. C., Wall, J. S., and Collier, R. J. (1994) Anthrax
protective antigen forms oligomers during intoxication of mammalian cells. J Biol Chem
269, 20607–20612.
63. Rainey, G. J. A., Wigelsworth, D. J., Ryan, P. L., Scobie, H. M., Collier, R. J., and
Young, J. A. T. (2005) Receptor-specific requirements for anthrax toxin delivery into
cells. Proc Natl Acad Sci USA 102, 13278–13283.
64. Lacy, D. B., D. J. Wigelsworth, R. A. Melnyk, S. C. Harrison, and R. J. Collier. 2004.
Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for
receptor in pH-dependent pore formation. Proc. Natl. Acad. Sci. USA 101:13147–
13151.

56

65. Lakowicz, Joseph, R.

Principles of Fluorescence Spectroscopy.

Springer Science+Business Media, LLC, 2006.

57

Print.

New York:

Glossary
<OPTIONAL: If Glossary not used, delete the entire page, including the following page
break>

58

Appendix
<OPTIONAL: If Appendix not used, delete the entire page including the following page
break>

59

Vita
Pedro Raymundo Jacquez Valenzuela was born August 14, 1985 in El Paso,
Texas, United States of America.

He was raised in El Paso, but also in a small town

outside of Chihuhua, San Guillermo, Chihuahua, Mexico, by his maternal grandparents.
He is the youngest of five and only male. He obtained his Bachelors of Science in
Microbiology from the University of Texas at El Paso on May, 2008.
In 2009, he joined the graduate program at the University of Texas at El Paso
under the mentorship of Dr. Jianjun Sun. He and Dr. Sun worked on understanding
the role and mechanism of the disulfide bonds in the Anthrax Toxin Receptor towards
anthrax pathogenesis. He was also a teaching assistant for senior level undergraduate
laboratories and also a lecturer for a non-since major’s biology course.

He also

participated in many conferences including the Rio Grande American Society of
Microbiology (2011, 2014), the Annual Biomedical Research Conference for Minority
Students (2014), and the Health Minorities and Heal Disparities Grantees’ Conference
(2014), in which he presented posters and gave talks about his research.
Finally, as a graduate student, he published two first authors articles on his
research, and contributed to another publication as a co-author. After graduating he
plans on joining a research company or government laboratory, to study and develop
better ways to detect bacterial pathogenesis.

Permanent address: 420 McCarthy Ave
El Paso, Texas 79915
This dissertation was typed by Pedro Raymundo Jacquez.
60

